Zacks Research Has Positive Forecast for APLS Q3 Earnings

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) - Investment analysts at Zacks Research increased their Q3 2025 earnings per share (EPS) estimates for Apellis Pharmaceuticals in a note issued to investors on Monday, June 30th. Zacks Research analyst R. Department now expects that the company will post earnings per share of ($0.43) for the quarter, up from their prior estimate of ($0.44). The consensus estimate for Apellis Pharmaceuticals' current full-year earnings is ($1.70) per share. Zacks Research also issued estimates for Apellis Pharmaceuticals' Q4 2025 earnings at ($0.40) EPS, FY2025 earnings at ($2.03) EPS, Q4 2026 earnings at ($0.41) EPS, FY2026 earnings at ($1.69) EPS and FY2027 earnings at ($0.43) EPS.

A number of other analysts have also commented on the company. Cantor Fitzgerald assumed coverage on Apellis Pharmaceuticals in a research note on Tuesday, April 29th. They set an "overweight" rating and a $44.00 price target on the stock. Royal Bank Of Canada lowered their price objective on Apellis Pharmaceuticals from $21.00 to $18.00 and set a "sector perform" rating for the company in a research report on Thursday, May 8th. Scotiabank lowered their price objective on Apellis Pharmaceuticals from $28.00 to $20.00 and set a "sector perform" rating for the company in a research report on Thursday, May 8th. Morgan Stanley raised their price objective on Apellis Pharmaceuticals from $25.00 to $26.00 and gave the stock an "equal weight" rating in a research report on Wednesday. Finally, Raymond James Financial downgraded Apellis Pharmaceuticals from a "strong-buy" rating to an "outperform" rating and lowered their price objective for the stock from $75.00 to $52.00 in a research report on Friday, May 9th. Nine equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Apellis Pharmaceuticals currently has a consensus rating of "Moderate Buy" and a consensus target price of $39.79.

Apellis Pharmaceuticals Trading Up 0.9%

Shares of APLS stock traded up $0.17 during mid-day trading on Wednesday, reaching $17.99. 891,120 shares of the stock traded hands, compared to its average volume of 2,347,184. The stock's fifty day simple moving average is $18.14 and its two-hundred day simple moving average is $23.70. Apellis Pharmaceuticals has a 1-year low of $16.10 and a 1-year high of $42.47. The company has a market cap of $2.26 billion, a price-to-earnings ratio of -10.05 and a beta of 0.67. The company has a quick ratio of 3.62, a current ratio of 4.08 and a debt-to-equity ratio of 2.76.

Apellis Pharmaceuticals (NASDAQ:APLS - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The company reported ($0.74) EPS for the quarter, missing analysts' consensus estimates of ($0.36) by ($0.38). Apellis Pharmaceuticals had a negative net margin of 28.83% and a negative return on equity of 99.19%. The firm had revenue of $149.90 million for the quarter, compared to analyst estimates of $197.61 million. During the same period in the previous year, the business posted ($0.54) earnings per share. The business's revenue for the quarter was down 3.2% compared to the same quarter last year.

Insiders Place Their Bets

In other Apellis Pharmaceuticals news, General Counsel David O. Watson sold 5,000 shares of Apellis Pharmaceuticals stock in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $18.77, for a total value of $93,850.00. Following the completion of the sale, the general counsel directly owned 133,730 shares in the company, valued at approximately $2,510,112.10. The trade was a 3.60% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 6.50% of the company's stock.

Institutional Investors Weigh In On Apellis Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the business. US Bancorp DE increased its holdings in shares of Apellis Pharmaceuticals by 70.0% during the fourth quarter. US Bancorp DE now owns 3,223 shares of the company's stock valued at $103,000 after acquiring an additional 1,327 shares in the last quarter. Steward Partners Investment Advisory LLC increased its holdings in shares of Apellis Pharmaceuticals by 2.0% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 115,045 shares of the company's stock valued at $3,671,000 after acquiring an additional 2,250 shares in the last quarter. Charles Schwab Investment Management Inc. increased its holdings in shares of Apellis Pharmaceuticals by 4.2% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 996,748 shares of the company's stock valued at $31,806,000 after acquiring an additional 40,386 shares in the last quarter. Victory Capital Management Inc. increased its holdings in shares of Apellis Pharmaceuticals by 36.5% during the fourth quarter. Victory Capital Management Inc. now owns 562,269 shares of the company's stock valued at $17,942,000 after acquiring an additional 150,363 shares in the last quarter. Finally, M&T Bank Corp bought a new stake in shares of Apellis Pharmaceuticals during the fourth quarter valued at approximately $216,000. 96.29% of the stock is currently owned by institutional investors.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).